Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021

Shah MA, Kennedy EB, Alarcon-Rozas AE, et al. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline [published correction appears in J Clin Oncol. 2023 Mar 20;:JCO2300441]. J Clin Oncol. 2023;41(7):1470–1491. https://doi.org/10.1200/JCO.22.02331

Li Y, Feng A, Zheng S, Chen C, Lyu J. Recent Estimates and Predictions of 5-Year Survival in Patients with Gastric Cancer: A Model-Based Period Analysis. Cancer Control. 2022 Jan-Dec;29:10732748221099227. https://doi.org/10.1177/10732748221099227. PMID: 35499497; PMCID: PMC9067041.

Lu, J., Wang, Q., Zhang, H. et al. Analysis of endoscopic and pathological features of 6961 cases of gastric cancer. Sci Rep 14, 7159 (2024). https://doi.org/10.1038/s41598-024-58018-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12–49. https://doi.org/10.3322/caac.21820. Epub 2024 Jan 17. Erratum in: CA Cancer J Clin. 2024 Mar-Apr;74(2):203. PMID: 38230766.

Quint LE, Bogot NR. Staging esophageal cancer. Cancer Imaging. 2008 Oct 4;8 Spec No A(Spec Iss A):S33–42. https://doi.org/10.1102/1470-7330.2008.9007. PMID: 18852079; PMCID: PMC2582495.

Marghalani AM, Bin Salman TO, Faqeeh FJ, Asiri MK, Kabel AM. Gastric carcinoma: Insights into risk factors, methods of diagnosis, possible lines of management, and the role of primary care. J Family Med Prim Care. 2020 Jun 30;9(6):2659-2663. https://doi.org/10.4103/jfmpc.jfmpc_527_20. PMID: 32984103; PMCID: PMC7491774.

Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013 Jul-Aug;63(4):232–48. https://doi.org/10.3322/caac.21185. PMID: 23818335.

Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21(26):7933–7943. https://doi.org/10.3748/wjg.v21.i26.7933

Testa U, Castelli G, Pelosi E. Esophageal Cancer: Genomic and Molecular Characterization, Stem Cell Compartment and Clonal Evolution. Medicines (Basel). 2017 Sep 14;4(3):67. https://doi.org/10.3390/medicines4030067. PMID: 28930282; PMCID: PMC5622402.

Sheikh S, D'souza J. A case of well-differentiated squamous cell carcinoma in an extraction socket. J Indian Soc Periodontol. 2012;16(4):602-605. https://doi.org/10.4103/0972-124X.106928

Article  PubMed  PubMed Central  Google Scholar 

Meng NL, Wang YK, Wang HL, Zhou JL, Wang SN. Research on the Histological Features and Pathological Types of Gastric Adenocarcinoma With Mucinous Differentiation. Front Med (Lausanne). 2022;9:829702. Published 2022 Mar 4. https://doi.org/10.3389/fmed.2022.829702

Ku GY. Next-generation sequencing in gastric or gastroesophageal adenocarcinoma. Transl Gastroenterol Hepatol. 2020;5:56. Published 2020 Oct 5. https://doi.org/10.21037/tgh.2020.01.09

Krill T, Baliss M, Roark R, et al. Accuracy of endoscopic ultrasound in esophageal cancer staging. J Thorac Dis. 2019;11(Suppl 12):S1602-S1609. https://doi.org/10.21037/jtd.2019.06.50

Kim TJ, Kim HY, Lee KW, Kim MS. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics. 2009;29(2):403-421. https://doi.org/10.1148/rg.292085106

Article  PubMed  Google Scholar 

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687–97. https://doi.org/10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19. Erratum in: Lancet. 2010 Oct 16;376(9749):1302. PMID: 20728210.

Indini A, Rijavec E, Grossi F. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. Int J Mol Sci. 2021 Apr 30;22(9):4774. https://doi.org/10.3390/ijms22094774. PMID: 33946310; PMCID: PMC8125530.

Kulangara K, Zhang N, Corigliano E, et al: Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med 143:330-337, 2019

Article  CAS  PubMed  Google Scholar 

Luo H, Lu J, Bai Y, et al: Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st randomized clinical trial. JAMA 326:916-925, 2021

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun JM, Shen L, Shah MA, et al: Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study. Lancet398:759-771, 2021

Article  CAS  PubMed  Google Scholar 

Janjigian YY, Shitara K, Moehler M, et al: First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 398:27-40, 2021

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vanneman M, Dranoff G: Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12:237-251, 2012

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234-247. https://doi.org/10.1016/S1470-2045(21)00692-6

Article  CAS  PubMed  Google Scholar 

Helber HA, Hada AL, Pio RB, Moraes PHZ, Gomes DBD. Immunotherapy-induced pneumonitis: cases report. Einstein (Sao Paulo). 2018 Jun 21;16(2):eRC4030. https://doi.org/10.1590/S1679-45082018RC4030. PMID: 29947645; PMCID: PMC6019244.

Yamaguchi T, Shimizu J, Oya Y, Watanabe N, Hasegawa T, Horio Y, Inaba Y, Fujiwara Y. Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis. Thorac Cancer. 2022 Mar;13(5):724–731. https://doi.org/10.1111/1759-7714.14308. Epub 2022 Jan 19. PMID: 35044093; PMCID: PMC8888158.

Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454. https://doi.org/10.1056/NEJMoa1200690

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shogbon AO, Hap J, Dretler R, Dalvi AG. Cryptogenic organizing pneumonia during adjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX) for colon cancer. J Pharm Pract. 2013;26(1):62-66. https://doi.org/10.1177/0897190012451929

Article  PubMed  Google Scholar 

Chandra D, Maini R, Hershberger DM. Cryptogenic Organizing Pneumonia. [Updated 2022 Sep 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507874/

Michel L, Ferdinandy P, Rassaf T. Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction. Curr Heart Fail Rep. Published online March 2, 2024. https://doi.org/10.1007/s11897-024-00652-2

Michel L, Rassaf T, Totzeck M. Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc. 2019 Sep 7;25:100420. https://doi.org/10.1016/j.ijcha.2019.100420. PMID: 31517036; PMCID: PMC6736791.

Rohatgi S, Jagannathan JP, Rosenthal MH, Kim KW, Ramaiya NH, Krajewski KM. Vascular toxicity associated with chemotherapy and molecular targeted therapy: what should a radiologist know? AJR Am J Roentgenol. 2014 Dec;203(6):1353-62. https://doi.org/10.2214/AJR.13.11967. PMID: 25415715.

Rahaghi FN, Minhas JK, Heresi GA. Diagnosis of Deep Venous Thrombosis and Pulmonary Embolism: New Imaging Tools and Modalities. Clin Chest Med. 2018;39(3):493-504. https://doi.org/10.1016/j.ccm.2018.04.003

Article  PubMed  PubMed Central  Google Scholar 

Stacey RB, Hundley WG. The Role of Cardiovascular Magnetic Resonance (CMR) and Computed Tomography (CCT) in Facilitating Heart Failure Management. Curr Treat Options Cardiovasc Med. 2013 Aug;15(4):373-86. https://doi.org/10.1007/s11936-013-0253-6. PMID: 23817725; PMCID: PMC3767383.

von Knobelsdorff-Brenkenhoff F, Schulz-Menger J. Cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology: a comprehensive summary and update. J Cardiovasc Magn Reson. 2023 Jul 24;25(1):42. https://doi.org/10.1186/s12968-023-00950-z. PMID: 37482604; PMCID: PMC10364363.

Aquaro GD, De Gori C, Faggioni L, Parisella ML, Cioni D, Lencioni R, Neri E. Diagnostic and prognostic role of late gadolinium enhancement in cardiomyopathies. Eur Heart J Suppl. 2023 Apr 26;25(Suppl C):C130-C136. https://doi.org/10.1093/eurheartjsupp/suad015. PMID: 37125322; PMCID: PMC10132607.

O’Brien AT, Gil KE, Varghese J, Simonetti OP, Zareba KM. T2 mapping in myocardial disease: a comprehensive review. J Cardiovasc Magn Reson. 2022 Jun 6;24(1):33. https://doi.org/10.1186/s12968-022-00866-0. PMID: 35659266; PMCID: PMC9167641.

Grigorian A, O'Brien CB. Hepatotoxicity Secondary to Chemotherapy. J Clin Transl Hepatol. 2014 Jun;2(2):95–102. https://doi.org/10.14218/JCTH.2014.00011. Epub 2014 Jun 15. PMID: 26357620; PMCID: PMC4521265.

O’Reilly M, Mellotte G, Ryan B, O’Connor A. Gastrointestinal side effects of cancer treatments. Ther Adv Chronic Dis. 2020 Nov 27;11:2040622320970354. https://doi.org/10.1177/2040622320970354. PMID: 33294145; PMCID: PMC7705778.

Alomari M, Al Ashi S, Chadalavada P, Khazaaleh S, Covut F, Al Momani L, Elkafrawy A, Padbidri V, Funchain P, Campbell D, Romero-Marrero C. Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival. Gastroenterology Res. 2022 Apr;15(2):56–66. https://doi.org/10.14740/gr1491. Epub 2022 Mar 12. PMID: 35572476; PMCID: PMC9076156.

Weingarden AR, Rubin SJS, Gubatan J. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World J Gastrointest Oncol. 2021 Aug 15;13(8):772-798. https://doi.org/10.4251/wjgo.v13.i8.772. PMID: 34457186; PMCID: PMC8371513.

Cappello G, Molea F, Campanella D, Galioto F, Russo F, Regge D. Gastrointestinal adverse events of immunotherapy. BJR Open. 2021 Oct 20;3(1):20210027. https://doi.org/10.1259/bjro.20210027. PMID: 35707753; PMCID: PMC9185848.

Gosangi B, McIntosh L, Keraliya A, Irugu DVK, Baheti A, Khandelwal A, Thomas R, Braschi-Amirfarzan M. Imaging features of toxicities associated with immune checkpoint inhibitors. Eur J Radiol Open. 2022 Aug 8;9:100434. https://doi.org/10.1016/j.ejro.2022.100434. PMID: 35967881; PMCID: PMC9372737.

Tzilas V, Poletti V, Bouros D. Reversed halo sign in radiation-induced organizing pneumonia: natural course of the underlying pathophysiology. Pulmonology. 2021 Sep-Oct;27(5):460–464. https://doi.org/10.1016/j.pulmoe.2020.12.015. Epub 2021 Apr 11. PMID: 33853753.

Otani K, Seo Y, Ogawa K. Radiation-induced organizing Pneumonia: A Characteristic Disease that Requires Symptom-Oriented Management. Int J Mol Sci. 2017 Jan 27;18(2):281. https://doi.org/10.3390/ijms18020281. PMID: 28134830; PMCID: PMC5343817.

Shionoya Y, Katsumata M, Kasai H, Shikano K, Hino A, Suzuki M, Abe M, Suzuki T. Radiation-induced organizing pneumonia caused by carbon-ion radiotherapy for lung cancer. Radiol Case Rep. 2023 Nov 22;19(2):567-571. https://doi.org/10.1016/j.radcr.2023.11.012. PMID: 38074441; PMCID: PMC10700827.

Gharzai L, Verma V, Denniston KA, Bhirud AR, Bennion NR, Lin C. Radiation Therapy and Cardiac Death in Long-Term Survivors of Esophageal Cancer: An Analysis of the Surveillance, Epidemiology, and End Result Database. PLoS One. 2016;11(7):e0158916. Published 2016 Jul 18. https://doi.org/10.1371/journal.pone.0158916

Peterzan MA, Rider OJ, Anderson LJ. The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure. Card Fail Rev. 2016 Nov;2(2):115–122. https://doi.org/10.15420/cfr.2016.2.2.115. PMID: 28785465; PMCID: PMC5490982.

Siaravas KC, Katsouras CS, Sioka C. Radiation Treatment Mechanisms of Cardiotoxicity: A Systematic Review. Int J Mol Sci. 2023 Mar 27;24(7):6272. https://doi.org/10.3390/ijms24076272. PMID: 37047245; PMCID: PMC10094086.

Ibrahim EH, Baruah D, Croisille P, Stojanovska J, Rubenstein JC, Frei A, Schlaak RA, Lin CY, Pipke JL, Lemke A, Xu Z, Klaas A, Brehler M, Flister MJ, Laviolette PS, Gore EM, Bergom C. Cardiac Magnetic Resonance for Early Detection of Radiation Therapy-Induced Cardiotoxicity in a Small Animal Model. JACC CardioOncol. 2021 Mar;3(1):113–130. https://doi.org/10.1016/j.jaccao.2020.12.006. Epub 2021 Mar 16. PMID: 33912843; PMCID: PMC8078846.

Nesheiwat Z, Akbar H, Kahloon A, et al. Radiation Esophagitis. [Updated 2023 May 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499920/#

Jelvehgaran P, Steinberg JD, Khmelinskii A, Borst G, Song JY, de Wit N, de Bruin DM, van Herk M. Evaluation of acute esophageal radiation-induced damage using magnetic resonance imaging: a feasibility study in mice. Radiat Oncol. 2019 Oct 30;14(1):188. https://doi.org/10.1186/s13014-019-1396-8. PMID: 31666092; PMCID: PMC6822441.

Daldrup-Link HE, Henning T, Link TM. MR imaging of therapy-induced changes of bone marrow. Eur Radiol. 2007 Mar;17(3):743–61. https://doi.org/10.1007/s00330-006-0404-1. Epub 2006 Sep 21. PMID: 17021706; PMCID: PMC1797072.

Klag T, Wehkamp J, Goetz M. Endoscopic Balloon Dilation for Crohn's Disease-Associated Strictures. Clin Endosc. 2017 Sep;50(5):429-436. doi: https://doi.org/10.5946/ce.2017.147. Epub 2017 Sep 29. PMID: 29017297; PMCID: PMC5642070.

Probst S, Abikhzer G, Chaussé G, Tamilia M. I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy. Mol Imaging Radionucl Ther. 2018 Jun 7;27(2):84–87. https://doi.org/10.4274/mirt.59454. PMID: 29889031; PMCID: PMC5996605.

Konradsson M, Nilsson M. Delayed emptying of the gastric conduit after esophagectomy. J Thorac Dis. 2019 Apr;11(Suppl 5):S835-S844. https://doi.org/10.21037/jtd.2018.11.80. PMID: 31080667; PMCID: PMC6503290.

Athanasiou A, Hennessy M, Spartalis E, Tan BHL, Griffiths EA. Conduit necrosis following esophagectomy: An up-to-date literature review. World J Gastrointest Surg. 2019 Mar 27;11(3):155-168. https://doi.org/10.4240/wjgs.v11.i3.155. PMID: 31057700; PMCID: PMC6478597.

Oezcelik A, Banki F, Ayazi S, et al. Detection of gastric conduit ischemia or anastomotic breakdown after cervical esophagogastrostomy: the use of computed tomography scan versus early endoscopy. Surg Endosc. 2010;24(8):1948-1951. https://doi.org/10.1007/s00464-010-0884-6

Article  PubMed  Google Scholar 

Crestanello JA, Deschamps C, Cassivi SD, et al. Selective management of intrathoracic anastomotic leak after esophagectomy. J Thorac Cardiovasc Surg 2005;129:254-60.

Article  PubMed  Google Scholar 

Brenkman HJ, Parry K, Noble F, et al. Hiatal Hernia After Esophagectomy for Cancer. Ann Thorac Surg. 2017;103(4):1055-1062. https://doi.org/10.1016/j.athoracsur.2017.01.026

Article  PubMed  Google Scholar 

Lung K, Carroll PA, Rogalla P, Yeung J, Darling G. Paraconduit Hernia in the Era of Minimally Invasive Esophagectomy: Underdiagnosed? Ann Thorac Surg. 2021 Jun;111(6):1812-1819. https://doi.org/10.1016/j.athoracsur.2020.07.047. Epub 2020 Oct 5. PMID: 33031780.